Trial Profile

A randomized, placebo-controlled Phase 3 study of VY-AADC in patients with Parkinson's disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Jul 2018 New trial record
17 Jul 2018 According to a Voyager Therapeutics media release, based on the feedback from a Type 2 meeting with the US FDA, the company plans to submit review a biologics license application (BLA) for VY-AADC based on the data of phase 2 study (297013). However, if the result from this study is supportive and did not met its primary endpoint, the BLA application will be also supported by this study, if able to achieve primary endpoint.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com